Apart from the MAPK pathway, we also observed that STK11 and KEAP1, which are also often co-mutated in KRAS-mutant NSCLC, are more frequently co-mutated with class II or III BRAF mutations compared to class I variants21. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.